Management of multifocal primary cutaneous CD30 + anaplastic large cell lymphoma

James M. Shehan, Amer N. Kalaaji, Svetomir Nenad Markovic, Iftikhar Ahmed

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Primary cutaneous CD30 + anaplastic large cell lymphoma in adults is rare, but the prognosis is generally excellent. Skin lesions may be localized or, less commonly, multifocal. Although not extensively reported, multifocal primary cutaneous anaplastic large cell lymphoma tends to relapse after systemic chemotherapy and is generally considered more prone to progress to extracutaneous involvement than the localized disease. We report the case of a 21-year-old woman with primary cutaneous CD30 + anaplastic large cell lymphoma manifesting as widespread papules and nodules. Despite remaining localized to the skin, the disease relapsed after multiple chemotherapy regimens and autologous stem-cell transplantation. Treatment with an experimental anti-CD30 monoclonal antibody was successful. Review of this case and similar cases illustrates that traditional combination chemotherapy may not be best. Newer treatments, including anti-CD30 monoclonal antibodies, show promise. However, further study is needed to develop optimal therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)103-110
Number of pages8
JournalJournal of the American Academy of Dermatology
Volume51
Issue number1
DOIs
StatePublished - Jul 2004

Fingerprint

Primary Cutaneous Anaplastic Large Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Monoclonal Antibodies
Drug Therapy
Stem Cell Transplantation
Combination Drug Therapy
Skin Diseases
Therapeutics
Recurrence
Skin

Keywords

  • ALCL
  • ALK
  • anaplastic large cell lymphoma
  • anaplastic lymphoma kinase
  • CHOP
  • cyclophosphamide, Adriamycin, vincristine, prednisone

ASJC Scopus subject areas

  • Dermatology

Cite this

Management of multifocal primary cutaneous CD30 + anaplastic large cell lymphoma. / Shehan, James M.; Kalaaji, Amer N.; Markovic, Svetomir Nenad; Ahmed, Iftikhar.

In: Journal of the American Academy of Dermatology, Vol. 51, No. 1, 07.2004, p. 103-110.

Research output: Contribution to journalArticle

@article{a45091fbb9d84784b4d284aa0d5c2a10,
title = "Management of multifocal primary cutaneous CD30 + anaplastic large cell lymphoma",
abstract = "Primary cutaneous CD30 + anaplastic large cell lymphoma in adults is rare, but the prognosis is generally excellent. Skin lesions may be localized or, less commonly, multifocal. Although not extensively reported, multifocal primary cutaneous anaplastic large cell lymphoma tends to relapse after systemic chemotherapy and is generally considered more prone to progress to extracutaneous involvement than the localized disease. We report the case of a 21-year-old woman with primary cutaneous CD30 + anaplastic large cell lymphoma manifesting as widespread papules and nodules. Despite remaining localized to the skin, the disease relapsed after multiple chemotherapy regimens and autologous stem-cell transplantation. Treatment with an experimental anti-CD30 monoclonal antibody was successful. Review of this case and similar cases illustrates that traditional combination chemotherapy may not be best. Newer treatments, including anti-CD30 monoclonal antibodies, show promise. However, further study is needed to develop optimal therapeutic strategies.",
keywords = "ALCL, ALK, anaplastic large cell lymphoma, anaplastic lymphoma kinase, CHOP, cyclophosphamide, Adriamycin, vincristine, prednisone",
author = "Shehan, {James M.} and Kalaaji, {Amer N.} and Markovic, {Svetomir Nenad} and Iftikhar Ahmed",
year = "2004",
month = "7",
doi = "10.1016/j.jaad.2003.12.028",
language = "English (US)",
volume = "51",
pages = "103--110",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Management of multifocal primary cutaneous CD30 + anaplastic large cell lymphoma

AU - Shehan, James M.

AU - Kalaaji, Amer N.

AU - Markovic, Svetomir Nenad

AU - Ahmed, Iftikhar

PY - 2004/7

Y1 - 2004/7

N2 - Primary cutaneous CD30 + anaplastic large cell lymphoma in adults is rare, but the prognosis is generally excellent. Skin lesions may be localized or, less commonly, multifocal. Although not extensively reported, multifocal primary cutaneous anaplastic large cell lymphoma tends to relapse after systemic chemotherapy and is generally considered more prone to progress to extracutaneous involvement than the localized disease. We report the case of a 21-year-old woman with primary cutaneous CD30 + anaplastic large cell lymphoma manifesting as widespread papules and nodules. Despite remaining localized to the skin, the disease relapsed after multiple chemotherapy regimens and autologous stem-cell transplantation. Treatment with an experimental anti-CD30 monoclonal antibody was successful. Review of this case and similar cases illustrates that traditional combination chemotherapy may not be best. Newer treatments, including anti-CD30 monoclonal antibodies, show promise. However, further study is needed to develop optimal therapeutic strategies.

AB - Primary cutaneous CD30 + anaplastic large cell lymphoma in adults is rare, but the prognosis is generally excellent. Skin lesions may be localized or, less commonly, multifocal. Although not extensively reported, multifocal primary cutaneous anaplastic large cell lymphoma tends to relapse after systemic chemotherapy and is generally considered more prone to progress to extracutaneous involvement than the localized disease. We report the case of a 21-year-old woman with primary cutaneous CD30 + anaplastic large cell lymphoma manifesting as widespread papules and nodules. Despite remaining localized to the skin, the disease relapsed after multiple chemotherapy regimens and autologous stem-cell transplantation. Treatment with an experimental anti-CD30 monoclonal antibody was successful. Review of this case and similar cases illustrates that traditional combination chemotherapy may not be best. Newer treatments, including anti-CD30 monoclonal antibodies, show promise. However, further study is needed to develop optimal therapeutic strategies.

KW - ALCL

KW - ALK

KW - anaplastic large cell lymphoma

KW - anaplastic lymphoma kinase

KW - CHOP

KW - cyclophosphamide, Adriamycin, vincristine, prednisone

UR - http://www.scopus.com/inward/record.url?scp=3142609056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142609056&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2003.12.028

DO - 10.1016/j.jaad.2003.12.028

M3 - Article

VL - 51

SP - 103

EP - 110

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 1

ER -